To study the clinical efficacy of syndrome differentiation treatment of gout with drug assisted moxibustion therapy. Methods:A total of 78 cases of gout patients from January 2015 to December 2016 in our hospital for treatment were selected as the object of study. The patients were divided into control group and study group according to the random number table method, with 39 cases in each group. The patients in the control group were treated with colchicine. The patients in the study group were treated with drug-assisted moxibustion therapy for 2 weeks. The patients were followed up for 1-3 months. The levels of serum creatinine (Cre), blood urea nitrogen (BUN), uric acid (UA) and quality of life were compared between the two groups before and after treatment. Results:After treatment, the VAS scores of the two groups were lower than those before treatment, and the study group was lower than the control group. The difference was statistically significant (P<0.05). The levels of Cre, BUN and UA in the study group were lower than those in the control group, and the difference was statistically significant (P<0.05). The scores of social function, physiological function, healthy self-cognition and psychological function of the study group were higher than those of the control group, and the difference was statistically significant (P<0.05). Conclusion:Drug-assisted moxibustion therapy based on syndrome differentiation treatment of gout has significant effects, and can effectively reduce the degree of pain in patients with regulation of serum Cre, BUN, UA levels, relieving clinical symptoms and signs and improving patient quality of life.